|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Rajski M, Vogel B, Baty F, Rochlitz C and
Buess M: Global gene expression analysis of the interaction between
cancer cells and osteoblasts to predict bone metastasis in breast
cancer. PLoS One. 7:e297432012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nemes S, Parris TZ, Danielsson A, et al:
Segmented regression, a versatile tool to analyze mRNA levels in
relation to DNA copy number aberrations. Genes Chromosomes Cancer.
51:77–82. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iafrate AJ, Feuk L, Rivera MN, et al:
Detection of large-scale variation in the human genome. Nat Genet.
36:949–951. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sebat J, Lakshmi B, Troge J, et al:
Large-scale copy number polymorphism in the human genome. Science.
305:525–528. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuiper RP, Ligtenberg MJ, Hoogerbrugge N
and Geurts van Kessel A: Germline copy number variation and cancer
risk. Curr Opin Genet Dev. 20:282–289. 2010. View Article : Google Scholar
|
|
7
|
Staaf J, Jonsson G, Ringner M, Baldetorp B
and Borg A: Landscape of somatic allelic imbalances and copy number
alterations in HER2-amplified breast cancer. Breast Cancer Res.
13:R1292011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bunyan DJ, Eccles DM, Sillibourne J, et
al: Dosage analysis of cancer predisposition genes by multiplex
ligation-dependent probe amplification. Br J Cancer. 91:1155–1159.
2004. View Article : Google Scholar
|
|
9
|
Hungermann D, Schmidt H, Natrajan R, et
al: Influence of whole arm loss of chromosome 16q on gene
expression patterns in estrogen receptor-positive, invasive breast
cancer. J Pathol. 224:517–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kai K, Zhang Z, Yamashita H, Yamamoto Y,
Miura Y and Iwase H: Loss of heterozygosity at the ATBF1-A locus
located in the 16q22 minimal region in breast cancer. BMC Cancer.
8:2622008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cleton-Jansen AM: E-cadherin and loss of
heterozygosity at chromosome 16 in breast carcinogenesis: different
genetic pathways in ductal and lobular breast cancer? Breast Cancer
Res. 4:5–8. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cleton-Jansen AM, Callen DF, Seshadri R,
et al: Loss of heterozygosity mapping at chromosome arm 16q in 712
breast tumors reveals factors that influence delineation of
candidate regions. Cancer Res. 61:1171–1177. 2001.PubMed/NCBI
|
|
13
|
Dorion-Bonnet F, Mautalen S, Hostein I and
Longy M: Allelic imbalance study of 16q in human primary breast
carcinomas using microsatellite markers. Genes Chromosomes Cancer.
14:171–181. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zou D, Yoon HS, Perez D, Weeks RJ,
Guilford P and Humar B: Epigenetic silencing in non-neoplastic
epithelia identifies E-cadherin (CDH1) as a target for
chemoprevention of lobular neoplasia. J Pathol. 218:265–272. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Caldeira JR, Prando EC, Quevedo FC, Neto
FA, Rainho CA and Rogatto SR: CDH1 promoter hypermethylation and
E-cadherin protein expression in infiltrating breast cancer. BMC
Cancer. 6:482006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berx G, Cleton-Jansen AM, Strumane K, et
al: E-cadherin is inactivated in a majority of invasive human
lobular breast cancers by truncation mutations throughout its
extracellular domain. Oncogene. 13:1919–1925. 1996.PubMed/NCBI
|
|
17
|
Berx G, Cleton-Jansen AM, Nollet F, et al:
E-cadherin is a tumour/invasion suppressor gene mutated in human
lobular breast cancers. EMBO J. 14:6107–6115. 1995.PubMed/NCBI
|
|
18
|
Kanai Y, Oda T, Tsuda H, Ochiai A and
Hirohashi S: Point mutation of the E-cadherin gene in invasive
lobular carcinoma of the breast. Jpn J Cancer Res. 85:1035–1039.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Paredes J, Albergaria A, Oliveira JT,
Jeronimo C, Milanezi F and Schmitt FC: P-cadherin overexpression is
an indicator of clinical outcome in invasive breast carcinomas and
is associated with CDH3 promoter hypomethylation. Clin Cancer Res.
11:5869–5877. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gamallo C, Moreno-Bueno G, Sarrio D,
Calero F, Hardisson D and Palacios J: The prognostic significance
of P-cadherin in infiltrating ductal breast carcinoma. Mod Pathol.
14:650–654. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kremmidiotis G, Baker E, Crawford J, Eyre
HJ, Nahmias J and Callen DF: Localization of human cadherin genes
to chromosome regions exhibiting cancer-related loss of
heterozygosity. Genomics. 49:467–471. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ho GH, Calvano JE, Bisogna M and Van Zee
KJ: Expression of E2F-1 and E2F-4 is reduced in primary and
metastatic breast carcinomas. Breast Cancer Res Treat. 69:115–122.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Filippova GN, Lindblom A, Meincke LJ, et
al: A widely expressed transcription factor with multiple DNA
sequence specificity, CTCF, is localized at chromosome segment
16q22.1 within one of the smallest regions of overlap for common
deletions in breast and prostate cancers. Genes Chromosomes Cancer.
22:26–36. 1998. View Article : Google Scholar
|
|
24
|
Matsutani N, Yokozaki H, Tahara E, et al:
Expression of telomeric repeat binding factor 1 and 2 and
TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int
J Oncol. 19:507–512. 2001.PubMed/NCBI
|
|
25
|
Broccoli D, Chong L, Oelmann S, et al:
Comparison of the human and mouse genes encoding the telomeric
protein, TRF1: chromosomal localization, expression and conserved
protein domains. Hum Mol Genet. 6:69–76. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tsuji K, Kawauchi S, Saito S, et al:
Breast cancer cell lines carry cell line-specific genomic
alterations that are distinct from aberrations in breast cancer
tissues: comparison of the CGH profiles between cancer cell lines
and primary cancer tissues. BMC Cancer. 10:152010. View Article : Google Scholar
|
|
27
|
Hazan RB, Qiao R, Keren R, Badano I and
Suyama K: Cadherin switch in tumor progression. Ann NY Acad Sci.
1014:155–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cavallaro U and Christofori G: Cell
adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev
Cancer. 4:118–132. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Birchmeier W and Behrens J: Cadherin
expression in carcinomas: role in the formation of cell junctions
and the prevention of invasiveness. Biochim Biophys Acta.
1198:11–26. 1994.PubMed/NCBI
|
|
30
|
Parker BS, Argani P, Cook BP, et al:
Alterations in vascular gene expression in invasive breast
carcinoma. Cancer Res. 64:7857–7866. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zanetta L, Corada M, Grazia Lampugnani M,
et al: Downregulation of vascular endothelial-cadherin expression
is associated with an increase in vascular tumor growth and
hemorrhagic complications. Thromb Haemost. 93:1041–1046.
2005.PubMed/NCBI
|
|
32
|
Vostrov AA and Quitschke WW: The zinc
finger protein CTCF binds to the APBbeta domain of the amyloid
beta-protein precursor promoter. Evidence for a role in
transcriptional activation. J Biol Chem. 272:33353–33359. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Filippova GN, Fagerlie S, Klenova EM, et
al: An exceptionally conserved transcriptional repressor, CTCF,
employs different combinations of zinc fingers to bind diverged
promoter sequences of avian and mammalian c-myc oncogenes. Mol Cell
Biol. 16:2802–2813. 1996.
|
|
34
|
Burcin M, Arnold R, Lutz M, et al:
Negative protein 1, which is required for function of the chicken
lysozyme gene silencer in conjunction with hormone receptors, is
identical to the multivalent zinc finger repressor CTCF. Mol Cell
Biol. 17:1281–1288. 1997.PubMed/NCBI
|
|
35
|
Filippova GN, Qi CF, Ulmer JE, et al:
Tumor-associated zinc finger mutations in the CTCF transcription
factor selectively alter tts DNA-binding specificity. Cancer Res.
62:48–52. 2002.PubMed/NCBI
|
|
36
|
Kanduri C, Pant V, Loukinov D, et al:
Functional association of CTCF with the insulator upstream of the
H19 gene is parent of origin-specific and methylation-sensitive.
Curr Biol. 10:853–856. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rasko JE, Klenova EM, Leon J, et al: Cell
growth inhibition by the multifunctional multivalent zinc-finger
factor CTCF. Cancer Res. 61:6002–6007. 2001.PubMed/NCBI
|
|
38
|
Ikeda MA, Jakoi L and Nevins JR: A unique
role for the Rb protein in controlling E2F accumulation during cell
growth and differentiation. Proc Natl Acad Sci USA. 93:3215–3220.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yamada K, Yagihashi A, Yamada M, et al:
Decreased gene expression for telomeric-repeat binding factors and
TIN2 in malignant hematopoietic cells. Anticancer Res.
22:1315–1320. 2002.PubMed/NCBI
|
|
40
|
Karlseder J, Broccoli D, Dai Y, Hardy S
and de Lange T: p53- and ATM-dependent apoptosis induced by
telomeres lacking TRF2. Science. 283:1321–1325. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yamada M, Tsuji N, Nakamura M, et al:
Down-regulation of TRF1, TRF2 and TIN2 genes is important to
maintain telomeric DNA for gastric cancers. Anticancer Res.
22:3303–3307. 2002.PubMed/NCBI
|
|
42
|
Coleman WB and Tsongalis GJ: Multiple
mechanisms account for genomic instability and molecular mutation
in neoplastic transformation. Clin Chem. 41:644–657.
1995.PubMed/NCBI
|
|
43
|
Cavenee WK: Tumor progression stage:
specific losses of heterozygosity. Princess Takamatsu Symp.
20:33–42. 1989.PubMed/NCBI
|
